Dabigatran Versus Warfarin With NVAF Who Undergo PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1120 participants.

Also called NCT03536611

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03536611
Other papers using this trial's data
  • Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI) BMC medicine, 2025-11-18 DOI, PubMed 41254594, PMC12625052 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03536611. Randomized; single masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2019-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
Acronym
COACH-AF-PCI
Intervention (Drug)
dabigatran
Intervention (Drug)
warfarin
Lead sponsor
Shenyang Northern Hospital (class: other)
Collaborator
Beijing Anzhen Hospital (class: other)
Collaborator
Second Affiliated Hospital of Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct03536611
Content hash
e20ed4421e8fbc1ea1761cf827fcd02c0d9575ea938ffdbf123d0c8b393a2147